InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Return on Capital Employed of 110.05% for Q1 2026, up 242.0% year-over-year from 32.18% in Q1 2025, and down 43.16% quarter-over-quarter from 76.87% in Q4 2025.
InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 110.05% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 242.0% year-over-year to 110.05%; the TTM figure through Mar 2026 stood at 110.05% (up 242.0% YoY), while the FY2025 annual figure was 66.99%, up 757.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 110.05%, down from 76.87% in the prior quarter.
- The five-year high for Return on Capital Employed was 52.02% in Q1 2024, with the low at 172.51% in Q3 2022.
- The 5-year median for Return on Capital Employed is 78.09% (2024), against an average of 94.03%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed surged 10517 bps in 2023, then plunged 6045 bps in 2025.
- InMed Pharmaceuticals' Return on Capital Employed stood at 118.71% in 2022, then soared by 49 bps to 60.98% in 2023, then plunged by 68 bps to 102.27% in 2024, then gained by 25 bps to 76.87% in 2025, then sank by 43 bps to 110.05% in 2026.
- Business Quant data shows INM's Return on Capital Employed at 110.05% in Q1 2026, 76.87% in Q4 2025, and 65.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | -115.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.05% |
| Dec 31, 2025 | -76.87% |
| Sep 30, 2025 | -65.43% |
| Jun 30, 2025 | -78.99% |
| Mar 31, 2025 | -112.47% |
| Dec 31, 2024 | -102.27% |
| Sep 30, 2024 | -74.77% |
| Jun 30, 2024 | -77.19% |
| Mar 31, 2024 | -52.02% |
| Dec 31, 2023 | -60.98% |
| Sep 30, 2023 | -67.34% |
| Jun 30, 2023 | -67.86% |
| Mar 31, 2023 | -106.69% |
| Dec 31, 2022 | -118.71% |
| Sep 30, 2022 | -172.51% |
| Jun 30, 2022 | -160.33% |